AstraZeneca Releases Coronavirus Vaccine Trial Plans
MONDAY, Sept. 21, 2020 (HealthDay News) — AstraZeneca is the latest drug company to release details about human tests of its coronavirus vaccine in response to public demand for such information.
Americans have increasing doubts about a coronavirus vaccine and experts are worried that an unproven or unsafe vaccine may be released prematurely due to pressure from President Donald Trump, The New York Times reported.
AstraZeneca’s clinical trials have prompted particular concern because the company has refused to provide details about serious neurological illnesses in two participants in Britain. The cases led the company to halt its trials twice. They’re still on hold in the U.S. but have resumed in Britain, Brazil, India and South Africa.
“If there are two cases, then this starts to look like a dangerous pattern,” Mark Slifka, a vaccine expert at Oregon Health and Science University, told the Times. “If a third case of neurological disease pops up in the vaccine group, then this vaccine may be done.”
AstraZeneca’s “release of these [trial] protocols seems to reflect some public pressure to do so,” Natalie Dean, a biostatistician and expert in clinical trial design for vaccines at the University of Florida, told the Times. “This is an unprecedented situation, and public confidence is such a huge part of the success of this endeavor.”
A vaccine with 50% effectiveness is AstraZeneca’s goal, according to the protocol released on the weekend. That’s the U.S. Food and Drug Administration’s threshold in its guidance for a coronavirus vaccine.
Moderna and Pfizer have also released information about clinical trials of their coronavirus vaccine candidates.
There’s a problem with all three companies’ plans, according to Dr. Eric Topol, a clinical trials expert at Scripps Research in San Diego. They all count relatively mild cases of COVID-19 when assessing vaccine effectiveness, which could lead to uncertainty about whether a vaccine prevents moderate or severe illness, Topol told the Times.
Copyright © 2019 HealthDay. All rights reserved.